PAI Pharma Executive and Leadership Team

Kurt Orlofski, the Chief Executive Officer at PAI Pharma, directs the overarching strategic vision for the manufacturing of generic oral liquid medications. By aligning corporate objectives with the needs of hospitals and long-term care facilities, the Chief Executive Officer ensures consistent production of high-quality suspensions and syrups. Kurt Orlofski manages the long-term growth trajectory, focusing on expanding the reach of unit-dose pharmaceutical products within the United States healthcare market. This leadership role involves constant collaboration with the Board to maintain the competitive position of the organization as a premier manufacturer of liquid generic pharmaceuticals. Through rigorous oversight of product development cycles, the Chief Executive Officer guarantees that all injectable medicines and specialty formulations meet stringent safety standards. By prioritizing patient-centric drug delivery solutions, the Chief Executive Officer drives the company toward sustained excellence in the pharmaceutical manufacturing sector while maintaining operational integrity across all institutional healthcare provider channels.

Thomas Reilly, the Chief Financial Officer at PAI Pharma, manages the fiscal health and capital allocation strategies required for large-scale pharmaceutical manufacturing. Overseeing the financial planning for the development and distribution of prescription generic medicines, the Chief Financial Officer ensures that the organization maintains robust liquidity to support ongoing production of oral solutions and elixirs. Thomas Reilly monitors the economic impact of supply chain fluctuations, providing the necessary data to optimize the manufacturing of unit-dose pharmaceuticals. This role involves direct interaction with institutional investors and government agencies to secure the financial stability of the company. By implementing advanced cost-control measures across the Greenville headquarters, the Chief Financial Officer maximizes profitability while supporting the expansion of the product portfolio. Through precise financial modeling and risk assessment, the Chief Financial Officer secures the resources needed to maintain the market leadership of the organization in the competitive landscape of generic pharmaceutical manufacturing.

Brandon Rockwell, the President & Chief Operating Officer at PAI Pharma, directs the daily manufacturing operations and logistics for the entire portfolio of oral liquid medications. Overseeing the production facilities, the President & Chief Operating Officer ensures that the manufacturing of suspensions, syrups, and semi-solid medications adheres to the highest quality standards for retail pharmacy chains and acute care facilities. Brandon Rockwell manages the integration of new drug delivery technologies into the existing manufacturing workflow to improve efficiency. This leadership role involves coordinating with internal teams to streamline the packaging and distribution of over-the-counter pharmaceutical products throughout the United States. By optimizing the operational throughput, the President & Chief Operating Officer supports the company mission of providing reliable medication access to institutional healthcare providers. Through constant monitoring of production metrics, the President & Chief Operating Officer maintains the operational excellence required to meet the high demand for generic pharmaceuticals across diverse healthcare settings.

Michael Elliott, the President at PAI Pharma, leads the commercial expansion and market development initiatives for the company. Focusing on the growth of the injectable medicines and specialty pharmaceutical formulations segment, the President drives the adoption of unit-dose products within long-term care organizations and government healthcare systems. Michael Elliott manages the relationships with key stakeholders to ensure that the product portfolio remains aligned with the evolving needs of the United States healthcare market. This leadership role involves architecting the go-to-market strategy for new generic medications, ensuring that the organization effectively reaches independent pharmacies and large-scale healthcare providers. By analyzing market trends and competitive dynamics, the President identifies new opportunities for product diversification. Through the execution of strategic partnerships, the President strengthens the market presence of the organization, ensuring that the company remains a trusted provider of high-quality generic pharmaceuticals for patients and healthcare professionals nationwide.